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Etiology and Spectrum of Non-Relapse Mortality after
Reduced Intensity Allogeneic Hematopoietic Stem Cell
Transplantation in Adults with Myeloid Neoplasms
Emily C. Eiten, Shahrukh Hashmi, Mark R. Litzow,
William Hogan, Dennis A. Gastineau, Mrinal Patnaik. Division
of Hematology, Mayo Clinic, Rochester, MN
Background: Reduced-intensity conditioning (RIC) provides
graft-versus-disease effect with less treatment related
toxicity, making allogeneic hematopoietic stem cell trans-
plantation (HSCT) available to more recipients. The objective
was to describe the etiology and spectrum of non-relapse
mortality (NRM) following RIC HSCT for myeloid neoplasms.
Methods: After due IRB approval, consecutive patients, who
underwent RIC HSCT for myeloid neoplasms between 2000
and 2014 at Mayo Clinic, Rochester were identiﬁed. RIC
regimens were melphalan/ﬂudarabine or busulfan/ﬂudar-
abine. Graft-versus-host disease (GVHD) prophylaxis was per
institutional standards. Cause of mortality was retrospec-
tively analyzed through clinical documentation.
Results: 200 patients, 125 (63%) males, median age 60
(range, 18 to 72) underwent RIC HSCT for myeloid neoplasms
(AML, 59% [77% in CR]; MDS, 30% [52%without excess blasts];
myeloﬁbrosis, 7.5%; and CML 3.5%). At last follow-up, 102
(51%) patients had died. Median follow-up was 14 months
(range, 0-111). Of the 102 patients, 41 (40%) patients had
disease relapse (AML, 28 [61% in prior CR]; MDS, 11[72% with
prior excess blasts]); and myeloﬁbrosis, 2 (5%).
NRM was documented in 59 (58%) of 102 patients that
had died and 2 patients were lost to follow-up. In 54 (92%) of
the 59 patients, death was attributed to transplant-related
complications (sepsis, 11 [20%]; multiple organ dysfunction
syndrome (MODS) and sepsis, 10 [19%]; respiratory failure
secondary to infection, 5 [9%]; acute GVHD, 9 [17%]; chronicFigure 1GVHD, 12 [22%]; intracranial hemorrhage from thrombocy-
topenia, 4 [7%]; diffuse alveolar hemorrhage, 2 [4%]; and graft
failure, 1 [2%]). Amongst acute GVHD deaths (67% grade 4- all
GI GVHD), CMV infection and steroid-induced myopathy
contributed to death. In patients with chronic GVHD (83%
severe), associated causes of death included respiratory
failure from obliterative bronchiolitis, encephalopathy, and
MODS from transplant-associated microangiopathy.
The remaining 5 NRM patients died of non-transplant
related complications; unrelated malignancies (4) and trau-
matic intracranial hemorrhage (1).
Conclusion: Although RIC increases access to transplant for
otherwise ineligible patients, it still poses signiﬁcant mor-
tality risk from disease relapse (20%) and transplant-related
complications (27%). No cases of sinusoidal obstruction
syndrome were seen in our series.517
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Background: CAR modiﬁed T-cell therapy is an engineered
immunotherapy that harnesses the power of the patient’s
immune system to ﬁght cancer. Although trials in this ther-
apy have been small to date, encouraging results have been
reported from phase I trials in acute lymphoblastic leukemia
and chronic lymphocytic leukemia.
Poor risk relapsed or refractory diffuse large B cell lym-
phoma (rel/ref DLBCL) is a novel area of investigation for the
use of CAR T-cell therapy. It is hypothesized that cellular
therapy can be optimized by giving CAR T-cells immediately.
Figure 2.
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lowed by ASCT.
Patients undergoing CAR T-cell therapy are prone to CRS
which can be fatal. C-reactive protein (CRP) has been iden-
tiﬁed as a surrogate marker for CRS.
Intervention: Patients with aggressive rel/ref DLBCL receive
BEAM conditioning followed by ASCTon day 0 and CAR T-cell
infusion on days +2 and +3 per institutional protocol 12-117.
CRP levels are monitored daily for trends, and close surveil-
lance for signs/symptoms of CRS is performed. An algorithm
to guide management of CRS is included in all our CAR T-cell
therapy protocols (Fig. 1).
Findings: To date, six patients have been treated on this
protocol. Two of the six patients had CRS and were treated
according to the management guideline, and both patients
had a peak CRP >20 (Fig. 2). All patients had neutrophil
engraftment at the expected time point and remain in
remission at a median follow-up of 6 months.
Discussion & Implications: Preliminary ﬁndings based on
limited data show encouraging results for use of CAR T-
cell therapy in this patient population. A correlation wasTable 1
Comparison of Pre and Post Intervention Times
Pre
Time To: n Median IQR
Vitals 24 4 2-11
Blood Culture 22 38 30-60
Antibiotics 20 114 93-168
Transfer to Unit 24 211 181-257
Figure 1. BPA to alert clinicians to BMT history and the need for immediate assessmen
Epic Systems Corporation. Used with permission.seen in incidence of CRS when CRP was >20. This has been
seen in previous studies and may help to better identify
patients at risk for developing CRS. The CRS management
algorithm serves as a guideline: the immunomodulatory
agents (speciﬁcally dexamethasone) included in the al-
gorithm run the risk of muting the action of the CAR T-
cells. Thus, the risk of implementing this algorithm needs
to be weighed against the risk of progression of lymphoid
malignancy. In this protocol, a lower threshold for acti-
vating the management algorithm is utilized as the risk of
death from CRS exceeds that of death due to primary
disease. This trial is ongoing, and updated results are
forthcoming.BMT ADMINISTRATORS/QUALITY
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A. Effect of Computerized Triage Support for Evaluation
and Treatment of Febrile Bone Marrow Transplant
Patients Who Present to the Emergency Department
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Background: Rapid evaluation and antibiotic therapy for
febrile bone marrow transplant (BMT) patients is critical
to decrease morbidity and mortality from infection, but
identifying these patients in a large medical system can be
challenging. This study measures the effect of computer-
ized triage support implemented in an EmergencyPost p-value
n Median IQR
39 5 3-9 0.32
33 41 25-66 0.45
34 79 61-135 <0.01
39 174 152-320 0.28
t. The BPA also sends pages to ED LIPs, charge nurse and the BMT team.  2014
